Report Scope:
The current report offers a comprehensive picture of the smart inhalers market. Smart inhalers prescribed for the treatment of asthma and COPD are included in the scope of the study. The report excludes the revenue of inhalers and sensors that operate independently. The focus of this report is instead the combined product, which consists of an inhaler and sensor and is called a smart inhaler; this is tracked and included in the report's current scope. The market size includes the revenue the smart inhaler generated for pharma companies. Digital companies merely provide the sensors to pharma companies; and pharma companies are the ones assembling smart inhalers and making them available.
The report explains the current and future market potential of smart inhalers. It offers a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, and market trends. The report covers market forecasts through 2024.
The report details market shares of smart inhalers based on the product, disease indication, and geography. Based on the product, the market is fragmented into dry powder inhaler (DPI)-based smart inhalers and metered-dose inhaler (MDI)-based smart inhalers.
By disease indication, the market is segmented into asthma and COPD.
By geography, the market has been segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Detailed analyses of major countries such as the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China, and India are covered in regional segments. For market estimates, data is provided for the year 2018 as the base year, 2019, and forecast through year-end 2024. Estimated values used are based on pharma manufacturers’ total revenues and estimated installations of smart inhalers. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.
The Report Includes:
- 18 data tables and 14 additional tables
- A descriptive overview of the global smart inhalers market
- Analyses of the global market trends, with data corresponding to market size for 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2024
- Country specific data and analysis for the United States, Canada, Germany, France, Italy, Spain, UK, China, Japan, India, and other emerging economies
- Latest information on the market potential for smart inhalers, opportunities and restraints, technological advancements, regulatory scenario, and other macroeconomic trends affecting the marketplace
- Key merger and acquisition deals, partnerships, agreements, collaborations, and joint ventures in the global smart inhalers market
- Estimation of market size and forecast, and market share analysis of smart inhalers based on the product, disease indication, and geographical region
- A brief outline on the impact of the COVID-19 pandemic on the global smart inhalers market and MedTech
- Detailed profiles of the major listed pharmaceutical companies, including AstraZeneca plc, Boehringer Ingelheim Gmbh, GlaxoSmithKline Plc, Novartis AG, and Teva Pharmaceutical Industries Ltd.
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
- Analyst's Credentials
- Custom Research
- Related Reports
Chapter 2 Summary and Highlights
- Highlights of the Market for Smart Inhalers
Chapter 3 Market Background
- Respiratory Inhalers
- Metered Dose Inhalers
- Dry Powder Inhaler
- Smart Inhalers
Chapter 4 Medical Devices Regulations
- Medical Device Definition and Classification
- Regulations in U.S.
- Regulations in Europe
- Regulations in Japan
Chapter 5 Market Dynamics
- Market Drivers
- Increasing Prevalence of Respiratory Diseases
- Rise in Geriatric Population
- Growing Collaboration between Pharma and Digital Health Companies
- Improved Technology: Leading to Development of Smart Inhalers
- Market Restraints
- Lack of Awareness Regarding Respiratory Diseases Symptoms
- Reduction in Product Adoption Due to Issues Concerning Data Security
Chapter 6 Impact of COVID-19 Pandemic
- Introduction
- Outbreak
- Progression of COVID-19
- Current Status and Impact on MedTech
- Elective and Noncritical Procedures
- Regulatory Delays, Clinical Trials and Product Launches
- Supply Chain Disruptions
Chapter 7 Market Breakdown by Product
- Global Market for Smart Inhalers by Product
- DPI-Based Smart Inhalers
- MDI-Based Smart Inhalers
Chapter 8 Market Breakdown by Disease Indication
- Global Market for Smart Inhalers by Disease Indication
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
Chapter 9 Market Breakdown by Region
- Global Market for Smart Inhalers by Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Chapter 10 Competitive Landscape
- Mergers and Acquisitions
- Agreements, Collaborations and Partnerships
Chapter 11 Company Profiles
- Astrazeneca Plc
- Boehringer Ingelheim Gmbh
- Glaxosmithkline Plc
- H&T Presspart Manufacturing Ltd.
- Novartis Ag
- Opko Health Inc.
- Teva Pharmaceutical Industries Ltd.
- Vectura Group Plc
Chapter 12 Appendix: List of Acronyms
List of Tables
Summary Table B: Global Market for Smart Inhalers, by Disease Indication, Through 2024
Summary Table A: Global Market for Smart Inhalers, by Product, Through 2024
Table 1: Class I and Class II Exempt Devices
Table 2: MDR Rules Classifications
Table 3: Number and Distribution of Persons Aged 60 Years or Over by Region, 2017 and 2050
Table 4: List of Major Pharma and Digital Health Companies Partnership and Collaboration
Table 5: Global Market for Smart Inhalers, by Product, Through 2024
Table 6: Global Market for Smart Inhalers, by Disease Indication, Through 2024
Table 7: Global Market for Smart Inhalers, by Region, Through 2024
Table 8: North American Market for Smart Inhalers, by Product, Through 2024
Table 9: North American Market for Smart Inhalers, by Disease Indication, Through 2024
Table 10: North American Market for Smart Inhalers, by Country, Through 2024
Table 11: European Market for Smart Inhalers, by Product, Through 2024
Table 12: European Market for Smart Inhalers, by Disease Indication, Through 2024
Table 13: European Market for Smart Inhalers, by Country, Through 2024
Table 14: Number of People Aged 65 Years or Over, by Geographic Region, 2019 and 2050
Table 15: Asia-Pacific Market Shares of Smart Inhalers, by Product, Through 2024
Table 16: Asia-Pacific Market for Smart Inhalers, by Disease Indication, Through 2024
Table 17: Asia-Pacific Market for Smart Inhalers, by Country, Through 2024
Table 18: Latin American Market for Smart Inhalers, by Product, Through 2024
Table 19: Latin American Market for Smart Inhalers, by Disease Indication, Through 2024
Table 20: Middle Eastern and African Market for Smart Inhalers, by Product, Through 2024
Table 21: Middle Eastern and African Market for Smart Inhalers, by Disease Indication, Through 2024
Table 22: AstraZeneca plc: Smart Inhalers Product Portfolio
Table 23: Boehringer Ingelheim GmbH: Smart Inhalers Product Portfolio
Table 24: GlaxoSmithKline plc: Smart Inhalers Product Portfolio
Table 25: H&T Presspart Manufacturing Ltd.: Smart Inhalers Product Portfolio
Table 26: Novartis AG: Smart Inhalers Product Portfolio
Table 27: OPKO Health, Inc.: Smart Inhalers Product Portfolio
Table 28: Teva Pharmaceutical Industries Ltd.: Smart Inhalers Product Portfolio
Table 29: Vectura Group plc: Smart Inhalers Product Portfolio
Table 30: Acronyms Used in the Smart Inhalers Industry
List of Figures
Summary Figure A: Global Market for Smart Inhalers, by Product, 2018–2024
Summary Figure B: Global Market Shares of Smart Inhalers, by Product, 2019
Summary Figure C: Global Market for Smart Inhalers, by Disease Indication, 2018–2024
Summary Figure D: Global Market Shares of Smart Inhalers, by Disease Indication, 2019
Figure 1: Benefits of Smart Inhaler and Associated Digital Services
Figure 2: Process for Marketing a Medical Device in the U.S.
Figure 3: Global Market Shares of Smart Inhalers, by Product, 2019
Figure 4: Global Market for DPI-Based Smart Inhalers, 2018-2024
Figure 5: Global Market for DPI-Based Smart Inhalers, by Region, 2018-2024
Figure 6: Global Market for MDI-Based Smart Inhalers, 2018-2024
Figure 7: Global Market for MDI-Based Smart Inhalers, by Region, 2018-2024
Figure 8: Global Market Shares of Smart Inhalers, by Disease Indication, 2019
Figure 9: Global Market for Smart Inhalers for Asthma, 2018-2024
Figure 10: Global Market for Smart Inhalers for COPD, 2018-2024
Figure 11: Global Market Shares of Smart Inhalers, by Region, 2019
Figure 12: North American Market Shares of Smart Inhalers, by Product, 2019
Figure 13: North American Market Shares of Smart Inhalers, by Disease Indication, 2019
Figure 14: North American Market Shares of Smart Inhalers, by Country, 2019
Figure 15: U.S. Market for Smart Inhalers, 2018-2024
Figure 16: Canadian Market for Smart Inhalers, 2018-2024
Figure 17: Impact of Asthma in Europe, Annual Mortality Rate (Per 100,000 People), 2016
Figure 18: Impact of COPD in Europe, Annual Mortality Rate (per 100,000 People), 2016
Figure 19: European Market Shares of Smart Inhalers, by Product, 2019
Figure 20: European Market Shares of Smart Inhalers, by Disease Indication, 2019
Figure 21: European Market Share for Smart Inhalers, by Country, 2019
Figure 22: German Market for Smart Inhalers, 2018-2024
Figure 23: U.K. Market for Smart Inhalers, 2018-2024
Figure 24: French Market for Smart Inhalers, 2018-2024
Figure 25: Italian Market for Smart Inhalers, 2018-2024
Figure 26: Percentage Change in Leading Causes of Death in Italy, 2005-2016
Figure 27: Spanish Market for Smart Inhalers, 2018-2024
Figure 28: Rest of Europe Market for Smart Inhalers, 2018-2024
Figure 29: Asia-Pacific Market Shares of Smart Inhalers, by Product, 2019
Figure 30: Asia-Pacific Market Shares of Smart Inhalers, by Disease Indication, 2019
Figure 31: Asia-Pacific Market Shares for Smart Inhalers, by Country, 2019
Figure 32: Japanese Market for Smart Inhalers, 2018-2024
Figure 33: Chinese Market for Smart Inhalers, 2018-2024
Figure 34: Indian Market for Smart Inhalers, 2018-2024
Figure 35: Rest of Asia-Pacific Market for Smart Inhalers, 2018-2024
Figure 36: Latin American Market Shares of Smart Inhalers, by Product, 2019
Figure 37: Latin American Market Shares of Smart Inhalers, by Disease Indication, 2019
Figure 38: Middle Eastern and African Market Shares of Smart Inhalers, by Product, 2019
Figure 39: Middle Eastern and African Market Shares of Smart Inhalers, by Disease Indication, 2019
Figure 40: AstraZeneca plc: Annual Revenue, 2015-2019
Figure 41: AstraZeneca plc: Revenue Share, by Business Unit, 2019
Figure 42: Boehringer Ingelheim GmbH: Annual Revenue, 2015-2019
Figure 43: Boehringer Ingelheim GmbH: Revenue Shares, by Business Unit, 2019
Figure 44: Boehringer Ingelheim GmbH: Revenue Shares, by Region, 2019
Figure 45: GlaxoSmithKline plc.: Annual Revenue, 2015-2019
Figure 46: GlaxoSmithKline plc: Revenue Share, by Region, 2019
Figure 47: Novartis AG.: Annual Revenue, 2015-2019
Figure 48: Novartis AG: Revenue Share, by Region, 2019
Figure 49: Novartis AG: Revenue Share, by Business Segment, 2019
Figure 50: OPKO Health Inc.: Annual Revenue, 2015-2019
Figure 51: Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2015-2019
Samples
LOADING...
Executive Summary
The global market's growth is attributed to factors such as the growing prevalence of respiratory diseases, a rise in the world’s geriatric population, growing collaboration between pharma and digital health companies, and improved technology leading to the development of smart inhalers.
Due to this alarming rise in the prevalence of respiratory disorders, the market is witnessing digital partnerships between software and pharma companies that are formed to offer technologically advanced smart inhalers. Various companies are stepping into the market to implement digital technology that can be further used to enhance respiratory disease management.
Companies Mentioned
- Astrazeneca Plc
- Boehringer Ingelheim Gmbh
- Glaxosmithkline Plc
- H&T Presspart Manufacturing Ltd.
- Novartis Ag
- Opko Health Inc.
- Teva Pharmaceutical Industries Ltd.
- Vectura Group Plc
